Literature DB >> 3374516

Halothane-caffeine contracture testing in neuromuscular diseases.

T D Heiman-Patterson1, H Rosenberg, J E Fletcher, A J Tahmoush.   

Abstract

The association of malignant hyperthermia (MH) with neuromuscular disorders has been recognized since 1970. These disorders include central core disease, Duchenne muscular dystrophy, myotonia congenita, myotonic dystrophy, nonspecific myopathies, and King-Denborough syndrome. In order to assess the anesthetic risk of MH in the neuromuscular population, we performed halothane and caffeine contracture testing for MH susceptibility on biopsied muscle removed from 25 consecutive neuromuscular patients during diagnostic evaluation. Positive contracture tests were found in 7 of 18 patients with myopathic disorders and 3 of 7 patients with neurogenic disorders. Two of our patients had anesthetic events suggesting MH. These findings suggest that myopathic and neuropathic disorders share pathogenic mechanisms with MH, resulting in positive contracture tests and possibly leading to clinical events during anesthesia. Although there is controversy regarding the interpretation of a positive contracture test, contracture testing remains the most widely accepted test for MH susceptibility. Thus, a variety of neuromuscular disorders may be associated with MH susceptibility, and caution should be exercised during anesthesia in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3374516     DOI: 10.1002/mus.880110507

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

1.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

2.  A rat model of spontaneous myopathy and malignant hyperthermia.

Authors:  L E Gonzalez; C V Meléndez-Vásquez; N A Gregson; S E File
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

Review 3.  Malignant hyperthermia susceptibility: biochemical basis for pathogenesis and diagnosis.

Authors:  P J O'Brien; A Klip; B A Britt; B I Kalow
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

Review 4.  Malignant hyperthermia.

Authors:  R Ben Abraham; P Adnet; V Glauber; A Perel
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

Review 5.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 6.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

7.  Trauma, systemic inflammatory response syndrome, dietary supplements, illicit steroid use and a questionable malignant hyperthermia reaction.

Authors:  John F Capacchione; Matthew C Radimer; Jeffrey S Sagel; Gregory P Kraus; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

8.  Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?

Authors:  Emmanuel Sagui; Coline Montigon; Amandine Abriat; Arnaud Jouvion; Sandrine Duron-Martinaud; Frédéric Canini; Fabien Zagnoli; David Bendahan; Dominique Figarella-Branger; Michel Brégigeon; Christian Brosset
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.